Devlin, M.

patient diflomotecan level grade dose level study topoisomerase i inhibitors bn 80915 administration pharmacokinetic toxicity cancer topoisomerase phase inhibitor neutropenia grade 4 neutropenia 1 patient 3 weeks cycle bioavailability antitumor activity tumor plasma bn 80942 adult patients activity disease disease progression 5 days 6 patients range phase i lactone 0.27 grade 1 dose levels urine grade 3 thrombocytopenia phase ii studies camptothecin 1999. homocamptothecin antitumor treatment topoisomerase i inhibitor analogue stability dosing dose reduction 0.35 novel pharmacodynamic adult percentage chemotherapy cl /f table hematological toxicity 0.27 mg lactone stability pharmacokinetic parameters 3 patients pharmacodynamic relationships 4 patients rd level ratio 12 patients fatigue baseline serum count relationship colon platelet e-ring therapy analysis plasma levels 7 days